Asset Details
Do you wish to reserve the book?
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Do you wish to request the book?
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
2014
Overview
In two phase 3 placebo-controlled, randomized trials in 1012 and 1040 patients with mild-to-moderate Alzheimer's disease, solanezumab, a humanized monoclonal antibody that preferentially binds soluble forms of amyloid, did not improve cognition or functional status.
Alzheimer's disease is associated with the accumulation of aggregated amyloid-beta (Aβ) peptide in the cerebral cortex and hippocampus. One approach to reducing brain amyloid involves increasing the clearance of Aβ by means of prolonged treatment with monoclonal antibodies directed against this peptide. In preclinical studies, a murine antibody that targeted the central domain of Aβ and was selective for soluble forms slowed Aβ deposition in a transgenic mouse model
1
; in another transgenic murine model, Aβ–antibody complexes were present in the cerebrospinal fluid (CSF) and plasma, and behavioral deficits were reversed without a decrease in amyloid plaques, as assessed by . . .
Publisher
Massachusetts Medical Society
Subject
/ Adult and adolescent clinical studies
/ Aged
/ Alzheimer Disease - cerebrospinal fluid
/ Alzheimer Disease - drug therapy
/ Amyloid beta-Peptides - blood
/ Amyloid beta-Peptides - cerebrospinal fluid
/ Antibodies, Monoclonal, Humanized - adverse effects
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Apolipoproteins E - genetics
/ Biological and medical sciences
/ Biomarkers - cerebrospinal fluid
/ Edema
/ Female
/ Gliosis
/ Humans
/ Male
/ Organic mental disorders. Neuropsychology
/ Plaques
/ Psychology. Psychoanalysis. Psychiatry
